Cyxone has announced results from its ongoing collaboration with Medical University of Vienna.
Cyxone and its research partner, the Medical University of Vienna, announced pre-clinical data further supporting T20K as a treatment for MS in combination with a kappa opioid receptor agonist (KORa).
Strong preclinical results
Previously Cyxone announced efficacy of T20K/KORa drug combination in a preventative model: a model where the drug is administered before disease onset preventing it from establishing. In a therapeutic model, the research animals develop disease symptoms over several days before the drugs are administered. The therapeutic model represents a higher bar for efficacy than a preventative model in MS. When T20K/KOR agonist combination was administered in the therapeutic model the efficacy was shown to be dose dependent and synergistic. This supports the concept of T20K/KORa combination therapy as a viable therapy for MS and warrants further investigation.
“We are excited to see the strong preclinical results supporting our patent application and the hypothesis for T20K/KORa combination therapy. With this combination we can explore a novel therapy for both early and more advanced MS potentially expanding the scope of treatment options for MS,” says Tara Heitner, CEO, Cyxone.
Photo of Tara Heitner: Cyxone
